Repligen (RGEN) Stock Forecast & Price Target

$147.07

+1.90 (+1.31%)

(As of 09/6/2024 ET)

Repligen - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 10 Analyst Ratings

Based on 10 Wall Street analysts who have issued ratings for Repligen in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 2 have given a hold rating, and 8 have given a buy rating for RGEN.

Consensus Price Target

$188.38
28.09% Upside

High Forecast	$220.00
Average Forecast	$188.38
Low Forecast	$155.00

According to the 10 analysts' twelve-month price targets for Repligen, the average price target is $188.38. The highest price target for RGEN is $220.00, while the lowest price target for RGEN is $155.00. The average price target represents a forecasted upside of 28.09% from the current price of $147.07.

Type	Current Forecast 9/8/23 to 9/7/24	1 Month Ago 8/9/23 to 8/8/24	3 Months Ago 6/10/23 to 6/9/24	1 Year Ago 9/8/22 to 9/8/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	7 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$188.38	$189.57	$197.75	$199.00
Forecasted Upside	28.09% Upside	12.05% Upside	18.83% Upside	20.95% Upside

Get Repligen Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter.

Ad Porter & Company

War on Elon Escalates…

A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.

RGEN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RGEN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Repligen Stock vs. The Competition

Type	Repligen	Medical Companies	S&P 500
Consensus Rating Score	2.80	2.77	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	28.09% Upside	1,207.61% Upside	11.35% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/27/2024	Wells Fargo & Company 3 of 5 stars	B. Couillard Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$180.00	+23.26%
8/5/2024	Benchmark 2 of 5 stars		Reiterated Rating	Hold
7/31/2024	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$190.00 ➝ $200.00	+18.34%
7/31/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$205.00 ➝ $185.00	+9.86%
7/31/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$190.00 ➝ $190.00	+13.70%
7/30/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$170.00 ➝ $170.00	+9.30%
Get the Latest News and Ratings for RGEN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.
6/26/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$180.00 ➝ $155.00	+25.86%
6/18/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Nambi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral
2/22/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$165.00 ➝ $207.00	+6.84%
2/15/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$210.00 ➝ $220.00	+6.10%
8/3/2023	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$207.00 ➝ $200.00	+16.73%
1/6/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$230.00 ➝ $200.00	+28.15%
11/2/2022	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Larew Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:13 PM ET.

RGEN Forecast - Frequently Asked Questions

What is Repligen's forecast for 2024?: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Repligen is $188.38, with a high forecast of $220.00 and a low forecast of $155.00.
Should I buy or sell Repligen stock right now?: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RGEN shares.
Does Repligen's stock price have much upside?: According to analysts, Repligen's stock has a predicted upside of 13.28% based on their 12-month stock forecasts.
Has Repligen been upgraded by Wall Street analysts recently?: Over the previous 90 days, Repligen's stock had 1 upgrade by analysts.
What analysts cover Repligen?: Repligen has been rated by research analysts at Benchmark, Deutsche Bank Aktiengesellschaft, Guggenheim, JPMorgan Chase & Co., Royal Bank of Canada, Stephens, UBS Group, and Wells Fargo & Company in the past 90 days.
Do Wall Street analysts like Repligen more than its competitors?: Analysts like Repligen more than other "medical" companies. The consensus rating score for Repligen is 2.80 while the average consensus rating score for "medical" companies is 2.77. Learn more on how RGEN compares to other companies.